Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.

Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.

Four deaths cast doubt on J&J’s multi-pronged KLK2 push.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.